Opicapone Reduces Homocysteine Levels in Patients with Parkinson’s Disease Treated with Levodopa Gel Infusion
Objective: Our study aims to assess the effect of an add-on treatment with catechol-O-methyl transferase (COMT) inhibitor, opicapone, on the plasmatic levels of homocysteine (HCY)…Changes in Parkinson’s Disease and Parkinsonian Syndromes A Comparative Retrospective Study in Kyrgyzstan
Objective: This study compares Parkinson's disease (PD) and parkinsonian syndromes (PS) in patients at a Kyrgyzstan university hospital. It analyzes data from 2016-2017 [1] and…Buspirone/zolmitriptan combination exerts synergistic reduction in dyskinesia without worsening Parkinson disease motor symptomatology
Objective: Levodopa-induced dyskinesias (LID) may be amenable to interventions with striatal serotonergic receptors. Preclinical evidence suggests that co-administration of serotonergic agonists with selective receptor properties…Changes in artistic style and Parkinson’s Disease
Objective: We present a Parkinson’s disease (PD) patient in whom dopamine agonists produced a dramatic change in her art style and production, and the subsequent…15-year effects of initiating treatment for Parkinson’s disease with dopamine agonists or monoamine oxidase B inhibitors compared with levodopa: final results of PD MED early disease randomisation
Objective: PD MED EARLY is a large, pragmatic trial aiming to determine which class of drug as initial treatment provides the most effective long-term control…A phase 2 randomized, double-blind, placebo-controlled trial of Ambroxol as a disease-modifying treatment for Parkinson’s disease dementia.
Objective: To evaluate the safety and tolerability of repurposing Ambroxol as a disease modifying treatment for Parkinson’s Disease Dementia (PDD). Background: Carrying a mutation in…Long-term effectiveness of adjuvant treatment with catechol-o-methyltransferase or monoamine oxidase B inhibitors compared with dopamine agonists in Parkinson’s disease uncontrolled by levodopa: final results of the PD MED LATER randomized clinical trial
Objective: PD MED LATER is a large, pragmatic trial aiming to determine which class of drug when added to levodopa provides the most effective control…Efficacy and safety of clonidine for the treatment of impulse control disorder in Parkinson’s disease: a multicentre, parallel, randomised, double blind, phase 2b clinical trial
Objective: We aimed to assess whether clonidine, a specific α2-adrenergic receptor agonist, would improve impulse controls disorders (ICDs). Background: ICDs are frequently encountered in Parkinson’s…Evaluation of cases of psychosis from opicapone safety data
Objective: Investigate the likelihood of association of Opicapone (OPC) with psychotic symptoms (other than hallucinations). Background: Neuropsychiatric symptoms frequently occur in Parkinson’s Disease (PD) patients,…Clinical Improvement and drastic reduction of Equivalent Dose of Levodopa (LEDD) in an Advanced Parkinson’s Disease Patient after Levodopa/Entacapone/Carbidopa Intestinal Gel (LECIG) Treatment
Objective: Describe a patient in which after starting continuous infusion of LECIG a large reduction of the LEDD is achieved. Background: Gastroparesis (GP) is one…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 32
- Next Page »